Nvidia AI chips targeted in China customs crackdown- FT
Christopher D. Maggiore, a director and ten percent owner of Zivo Bioscience Inc (NASDAQ:ZIVO), acquired 23,682 shares of common stock on October 8, 2025. The shares were purchased at $12.01, totaling $284,420. The purchase comes as the stock trades at $13.01, up from the insider’s entry price, though still down 44% year-to-date. According to InvestingPro analysis, ZIVO, with a market cap of $49.7 million, shows strong revenue growth despite remaining unprofitable.
Following the transaction, Maggiore directly owns 517,526 shares of Zivo Bioscience. InvestingPro data reveals the stock typically moves counter to market trends and exhibits high volatility, with 6 additional exclusive insights available for subscribers.
In other recent news, Zivo Bioscience, Inc. has announced a $2 million convertible debt offering. The company has already issued a bridge promissory note worth $250,000, along with a warrant for the purchase of 1,793 shares of its common stock to an accredited investor. These unsecured convertible notes carry an annual interest rate of 10%, compounded annually. Investors have the option to request payment on or after a qualified equity financing of at least $5 million or two years from the date of issuance. If the notes are still outstanding at that time, they will automatically convert into common shares at the lower of the closing price on the date of issuance or 80% of the price per share in the qualified financing. This development marks a significant financial maneuver for Zivo Bioscience as it seeks to raise capital.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.